Recombinant Human LILRB2/CD85d/ILT4 Domain1&2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln22-Val229.
Molecular Weight:
The protein has a predicted MW of 24.2 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Tag:
C-His
UniProt:
AAL36991.1
Buffer:
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Expression System:
HEK293
Purity:
> 90% as determined by Bis-Tris PAGE,> 90% as determined by HPLC
Form:
Lyophilized
Sequence:
Gln22-Val229
Target:
LILRB2/CD85d/ILT4
Human HLA-G Complex Tetramer, His Tag immobilized on CM5 Chip can bind Human LILRB2 Domain1&2, His Tag with an affinity constant of 6.5uM as determined in a SPR assay (Biacore T200).
Serial dilutions of Anti-LILRB2 Antibody were added into Human LILRB2 Domain1&2, His Tag : Biotinylated Human HLA-G Complex Tetramer, His Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.43ug/ml.
Immobilized Human LILRB2 Domain1&2, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 3.1ng/ml determined by ELISA (QC Test).
The purity of-Human LILRB2 Domain 1&2 is greater than 90% as determined by SEC-HPLC.
Human LILRB2 Domain 1&2 on Bis-Tris PAGE under reduced condition. The purity is greater than 90%.
* VAT and and shipping costs not included. Errors and price changes excepted
